ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1445

Citrulline Reactive B Cells Are Present in the Lungs of Risk RA and Early Untreated RA

Vijay Joshua1, Malena Loberg-Haarhaus2, Akilan Krishnamurthy1, Meng Sun3, Christina Gerstner4, Aase Hensvold5, Khaled Amara1, Lena Israelsson1, Ragnhild Stålesen6, Bence Rethi7, Magnus Sköld7, Johan Grunewald1, Heidi Wähämaa1, Caroline Grönwall1, Vivianne Malmström8 and Anca Catrina5, 1Karolinska Institutet, Stockholm, Sweden, 2Rheumatology clinic, Karolinska University Hospital, Stockholm, Sweden, Stockholm, Stockholms Lan, Sweden, 3Karolinska University Hospital and Karolinska Insitutet, Stockholm, Sweden, 4Division of Rheumatology, Department of Medicine,Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden, 5Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, Stockholm, Stockholms Lan, Sweden, 6Karolinska Institute, Stockholm, Sweden, 7Karolinska Institutet, Stockholm, 8Karolinska Institutet, Stockholm, Stockholms Lan, Sweden

Meeting: ACR Convergence 2020

Keywords: Autoantibody(ies), rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2020

Title: Plenary Session III (1441–1446)

Session Type: Plenary Session

Session Time: 11:30AM-1:00PM

Background/Purpose: Structural changes, increased tissue citrullination, signs of local inflammation and anti-citrullinated protein autoantibodies (ACPA) are present in the pulmonary compartment of early untreated seropositive rheumatoid arthritis (RA). These findings provide evidence of a potential role for the lungs in generation and initiation of RA-associated autoimmunity. Here we aimed to investigate the presence of citrulline-reactive B cells in the lung compartment of early untreated RA patients by single-cell cloning of monoclonal antibodies (mAbs) from lung-derived B cells.

Methods: Bronchoalveolar lavage (BAL) fluid cells were obtained from ACPA positive individuals with arthralgia (n=4), early untreated ACPA positive RA (n=3) and ACPA negative RA (n=5) patients at the time of diagnosis. CD19+ B cells were single cell sorted by flow cytometry. Immunoglobulin heavy and light chain variable regions were PCR amplified, sequenced, and analyzed by V-Quest and IgBLAST towards the IMGT database to annotate variable gene usage. Sequences having high somatic hypermutations (SHM) and Fab N-glycosylation sites were selected to be cloned and expressed as human IgG1 recombinant mAbs. Citrulline reactivity was determined by CCP2 assay and in-house ELISA against citrullinated and native peptides from vimentin, a-enolase, fibrinogen and filaggrin. Polyreactivity was determined by reactivity against double stranded DNA, bacterial lipopolysaccharides (LPS) and insulin. The functional properties of mAbs were analyzed in osteoclastogenesis assay, fibroblast migration assay and neutrophil binding assay.

Results: Significant higher proportion of CD19+ B cells were found in ACPA positive compared to ACPA negative BAL (median 6.7% vs 0.79%). PCR amplification and subsequent BCR sequencing from 8 individuals yielded 581 paired heavy and light chain sequences. 49 monoclonal antibodies (from 5 individuals) were selected for expression based on high number of SHM and predicted Fab N-linked glycosylation. Notably, four of these selected mAbs (8%; 2 antibodies from each patient, one risk RA and one early untreated RA) were determined to be ACPAs by CCP2 ELISA. The 4 ACPAs had varying ACPA fine-specificity against citrullinated a-enolase, filaggrin, vimentin and fibrinogen peptides without any native peptide binding. All the 4 monoclonal ACPAs were negative in polyreactivity test. Clone L204:01A01 and L201:11C11 but not clone L201:10D07 and L204:05E10 bound to activated neutrophils (49.75% for clone A01 and 22.3% for clone C11). Clone L204:01A01 and L204:05E10 but not L201:10D07 and L201:11C11 induced osteoclastogenesis with a fold increase of 1.5 and 1.9 respectively. Clone L204:01A01 and L201:10D07 but not L201:11C11 and L204:05E10 promoted fibroblasts migration with a fold increase of 1.4 and 1.5 respectively.

Conclusion: We demonstrate for the first time that citrulline-reactive B cells producing pathogenic ACPAs are present in the lung compartment of seropositive individuals at risk for or having early untreated RA. This provides a strong link between the lung and the adaptive autoreactive response in RA, and support the hypothesis of the lung as one of the key sites of initiation and propagation of disease in RA.


Disclosure: V. Joshua, None; M. Loberg-Haarhaus, None; A. Krishnamurthy, None; M. Sun, None; C. Gerstner, None; A. Hensvold, None; K. Amara, None; L. Israelsson, None; R. Stålesen, None; B. Rethi, None; M. Sköld, None; J. Grunewald, None; H. Wähämaa, None; C. Grönwall, None; V. Malmström, Pfizer, 2; A. Catrina, None.

To cite this abstract in AMA style:

Joshua V, Loberg-Haarhaus M, Krishnamurthy A, Sun M, Gerstner C, Hensvold A, Amara K, Israelsson L, Stålesen R, Rethi B, Sköld M, Grunewald J, Wähämaa H, Grönwall C, Malmström V, Catrina A. Citrulline Reactive B Cells Are Present in the Lungs of Risk RA and Early Untreated RA [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/citrulline-reactive-b-cells-are-present-in-the-lungs-of-risk-ra-and-early-untreated-ra/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/citrulline-reactive-b-cells-are-present-in-the-lungs-of-risk-ra-and-early-untreated-ra/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology